Assessment of Safety of a Supplement Containing Mushroom Chitosan in Case of Excess Ingestion

Assessment of Safety of a Supplement Containing Mushroom Chitosan in Case of Excess Ingestion - Safety of a Supplement Containing Mushroom Chitosan

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017133

Enrollment

Registered

2015-04-14

Start date

2008-06-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Safty varification of a supplement containing mushroom chitosan

Interventions

Oral ingestion of the test product (4 weeks)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: [1]Japanese males and females aged 20-59 years [2]Individuals whose BMI is less than 25 kg/m^2 (12 subjects) [3]Individuals whose BMI is over 25 kg/m^2 (12subjects)

Exclusion criteria

Exclusion criteria: [1]Individuals using or will use medical products [2]Individuals who had a habit to ingest health-promoting foods [3]Individuals who are or are posslibly, or are lactating [4]Individuals who excessively take alcohol [5]Individuals who have symptoms of allergy to the test product [6]Individuals who participate in other clinical studies [7]Individuals who have a history of serious hepatopathy, kidney damage, heart disease and hematological disease [8]Individuals with serious anemia [9]Individuals who had been administrated contrast material (ex. barium) in the past 2 months or will be administrated during the test period

Design outcomes

Primary

Measure	Time frame
Body structure Blood pressure Pulsation Blood biochemistry test Urine analysis Doctor's questions	—

Countries

Japan

Contacts

Public ContactTES Holdings Co., Ltd.

TES Holdings Co., Ltd. Department of Clinical Trial

info@tes-h.co.jp03-6801-8480

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026